|
Risk Factors for Initial Low Voriconazole Trough Level in Routine Therapeutic Drug Monitoring (click for details) |
|
|
|
In Vitro Activity of Antifungal Drugs against a Global Collection of 28 Clinical and Environmental Exserohilum Species Isolates (click for details) |
|
|
|
Assessing the in vivo Efficacy of Micafungin Against Candida glabrata with fks Mutations Conferring Moderate Resistance (click for details) |
|
|
|
PolyAmp: A Novel Polymer Complexed Formulation of Amphotericin B (click for details) |
|
|
|
Efficacy of Caspofungin or Voriconazole with Cefoperazone-Sulbactam or Piperacillin-Tazobactam in Neutropenic Murine Invasive Candidiasis Model and Its Relation to Cytokine Levels (click for details) |
|
|
|
In Vitro Interaction Between Isavuconazole and Micafungin or Amphotericin B against Medically Important Moulds (click for details) |
|
|
|
Phase 3 Pharmacokinetics (PK) and Safety Study of Posaconazole (POS) IV in Patients (Pts) at Risk for Invasive Fungal Infection (IFI) (click for details) |
|
|
|
Anti-biofilm Efficacy of Liposomal Amphotericin B and Echinocandin Catheter Lock Solutions against Candida Species (click for details) |
|
|
|
Blood Concentrations and Toxicity of Voriconazole and its Metabolites (click for details) |
|
|
|
Activity of Isavuconazole, Amphotericin B, and Micafungin Alone and in Combination against Exserohilum rostratum (click for details) |
|
|
